U.S. Markets close in 6 hrs 9 mins

Gilead Stock Could Surge to $84, Says Analyst

Teresa Rivas

RBC Capital Markets analyst Brian Abrahams reiterated an Outperform rating and $84 price target on the biotech’s stock.